je.st
news
Tag: patients
Ariad Pharma Discontinues Phase III Trial of Ponatinib (Iclusig) in Leukemia Patients
2013-10-20 13:07:47| Biotech - Topix.net
Ariad Pharmaceuticals, Inc. has announced that it is discontinuing the phase III EPIC trial of ponatinib in patients with newly diagnosed chronic myeloid leukemia .
Tags: iii
trial
phase
patients
ABRAXANE Phase III Study of Patients with Metastatic Pancreatic...
2013-10-17 14:14:39| Biotech - Topix.net
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine .
Tags: study
iii
phase
patients
New Breast Cancer Gene Test Gives Patients More Options
2013-10-15 19:32:39| Biotech - Topix.net
A new test has been introduced to screen for inherited forms of breast cancer, offering patients an alternative to the test developed by Myriad Genetics, which was long the sole option available.
Tags: options
test
cancer
patients
Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
2013-10-14 23:02:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind. Merck and Endocytes Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. Language: English Contact: MerckMedia:Caroline Lappetito,267-305-7639Caroline.Lappetito@Merck.comorClaire Mulhearn, 908-423-7425Claire.Mulhearn@Merck.comorInvestors:Carol Ferguson, 908-423-4465Carol.Ferguson@Merck.comorJustin Holko, 908-423-5088Justin_Holko@Merck.comorEndocyteMedia:Tony Russo, 212-845-4251Tony.Russo@Russopartnersllc.comorMartina Schwarzkopf, 212-845-4292Martina.Schwarzkopf@Russopartnersllc.comorInvestors:Stephanie Ascher, 212-362-1200Stephanie@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: of
results
journal
published
Street Roots: Leave the patients to us: Is Nevada unloading its mentally ill in Oregon?, 10/10/13
2013-10-11 21:43:17| PortlandOnline
Tags: street
leave
patients
oregon
Sites : [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] next »